FY2025 EPS Estimates for XENE Decreased by Analyst

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Xenon Pharmaceuticals in a research note issued to investors on Tuesday, August 12th. Cantor Fitzgerald analyst J. Schimmer now expects that the biopharmaceutical company will post earnings of ($3.85) per share for the year, down from their previous estimate of ($3.43). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Cantor Fitzgerald also issued estimates for Xenon Pharmaceuticals’ FY2026 earnings at ($4.08) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same quarter last year, the business posted ($0.75) EPS.

Other analysts have also issued reports about the stock. Wall Street Zen lowered shares of Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 21st. Royal Bank Of Canada decreased their target price on shares of Xenon Pharmaceuticals from $57.00 to $55.00 and set an “outperform” rating on the stock in a research report on Tuesday. Chardan Capital reiterated a “buy” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday. Needham & Company LLC reduced their price target on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Finally, William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Monday, May 5th. One research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.20.

Xenon Pharmaceuticals Stock Performance

Shares of Xenon Pharmaceuticals stock opened at $38.23 on Thursday. The firm’s 50-day simple moving average is $32.59 and its 200-day simple moving average is $34.06. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $46.00. The firm has a market cap of $2.95 billion, a P/E ratio of -10.77 and a beta of 1.16.

Hedge Funds Weigh In On Xenon Pharmaceuticals

A number of large investors have recently modified their holdings of XENE. Farther Finance Advisors LLC acquired a new position in shares of Xenon Pharmaceuticals during the second quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Xenon Pharmaceuticals during the first quarter worth approximately $30,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Xenon Pharmaceuticals during the second quarter worth approximately $32,000. GF Fund Management CO. LTD. acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth approximately $63,000. Finally, Quarry LP acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth approximately $78,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.